Key Takeaway
Comprehensive safety review finding purified shilajit well-tolerated at doses up to 500mg/day for 90 days, with no clinically significant adverse effects in human studies.
Summary
This review examined the safety and efficacy data for purified shilajit (PrimaVie) across multiple studies. The authors assessed clinical trials, toxicology studies, and traditional use evidence.
The review found consistent safety across human trials at doses of 250-500mg daily for periods up to 90 days. No significant adverse effects were reported in controlled studies.
The authors concluded that purified, processed shilajit appears safe for human consumption when quality-controlled products are used, though they noted the importance of avoiding raw, unprocessed shilajit due to contamination risks.
Methods
- Comprehensive literature review
- Analysis of clinical trial safety data
- Review of toxicology studies (acute and chronic)
- Assessment of traditional use evidence
- Focus on purified/processed shilajit (PrimaVie)
Key Results
- No significant adverse effects in human trials
- Safe at doses up to 500mg/day for 90 days
- Acute oral toxicity: LD50 >2,000 mg/kg in rats
- No mutagenic or genotoxic effects observed
- No significant changes in hematological or biochemical parameters
- Traditional use supports long-term safety
Limitations
- Limited long-term human safety data (>90 days)
- Most data from manufacturer-sponsored studies
- Does not address raw/unprocessed shilajit safety
- Limited data in special populations (elderly, children)
- Cannot generalize to all shilajit products on market